Cargando…

The Soluble Guanylate Cyclase Stimulator BAY 41-2272 Attenuates Transforming Growth Factor β1-Induced Myofibroblast Differentiation of Human Corneal Keratocytes

Corneal transparency, necessary for vision and depending on the high organization of stromal extracellular matrix, is maintained by keratocytes. Severe or continuous corneal injuries determine exaggerated healing responses resulting in the formation of irreversible fibrotic scars and vision impairme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosa, Irene, Fioretto, Bianca Saveria, Romano, Eloisa, Buzzi, Matilde, Mencucci, Rita, Marini, Mirca, Manetti, Mirko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737374/ https://www.ncbi.nlm.nih.gov/pubmed/36499651 http://dx.doi.org/10.3390/ijms232315325

Ejemplares similares

The soluble guanylyl cyclase stimulator BAY 41-2272 increases differentiation and function of brown adipocytes
por: Etzrodt, Jennifer, et al.
Publicado: (2013)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

Mechanisms of relaxant activity of BAY 41-2272 in rat tracheal smooth muscle in vitro
por: Toque, Haroldo AF, et al.
Publicado: (2009)

New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy
por: Romano, Eloisa, et al.
Publicado: (2021)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells
por: Adderley, Shaquria P., et al.
Publicado: (2012)

BAY 41-2272 activates host defence against local and disseminated Candida albicans infections
por: Soeiro-Pereira, Paulo Vítor, et al.
Publicado: (2015)

NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272
por: Becker, Eva Maria, et al.
Publicado: (2001)

Lymphatic Endothelial-to-Myofibroblast Transition: A Potential New Mechanism Underlying Skin Fibrosis in Systemic Sclerosis
por: Rosa, Irene, et al.
Publicado: (2023)

Extracellular Lactic Acidosis of the Tumor Microenvironment Drives Adipocyte-to-Myofibroblast Transition Fueling the Generation of Cancer-Associated Fibroblasts
por: Andreucci, Elena, et al.
Publicado: (2023)

Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications
por: Manetti, Mirko, et al.
Publicado: (2019)

Mapping of the sGC Stimulator BAY 41-2272 Binding Site on H-NOX Domain and Its Regulation by the Redox State of the Heme
por: Makrynitsa, Garyfallia I., et al.
Publicado: (2022)

Inhaled and intravenous application of a stimulator of the soluble guanylate cyclase (BAY 41-8543) reduces pulmonary vascular resistance in a model of septic shock
por: Kronas, Nils, et al.
Publicado: (2011)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011)

Keratocyte-Derived Myofibroblasts: Functional Differences With Their Fibroblast Precursors
por: Acosta, Ana C., et al.
Publicado: (2023)

Hypoxia reduces TGFβ1-induced corneal keratocyte myofibroblast transformation
por: Xing, Dongmei, et al.
Publicado: (2009)

Experimental Models for Investigating Intra-Stromal Migration of Corneal Keratocytes, Fibroblasts and Myofibroblasts
por: Petroll, Walter Matthew, et al.
Publicado: (2012)

Telocytes in normal and keratoconic human cornea: an immunohistochemical and transmission electron microscopy study
por: Marini, Mirca, et al.
Publicado: (2017)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis
por: Manetti, Mirko, et al.
Publicado: (2022)

Adipose-derived stem cells: Pathophysiologic implications vs therapeutic potential in systemic sclerosis
por: Rosa, Irene, et al.
Publicado: (2021)

Circulating Neurovascular Guidance Molecules and Their Relationship with Peripheral Microvascular Impairment in Systemic Sclerosis
por: Romano, Eloisa, et al.
Publicado: (2022)

Increased Circulating Soluble Junctional Adhesion Molecules in Systemic Sclerosis: Association with Peripheral Microvascular Impairment
por: Romano, Eloisa, et al.
Publicado: (2022)

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review
por: Fioretto, Bianca Saveria, et al.
Publicado: (2023)

BAY 41-2272 Attenuates CTGF Expression via sGC/cGMP-Independent Pathway in TGFβ1-Activated Hepatic Stellate Cells
por: Chen, Po-Jen, et al.
Publicado: (2020)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Soluble guanylate cyclase activator BAY 54–6544 improves vasomotor function and survival in an accelerated ageing mouse model
por: Ataei Ataabadi, Ehsan, et al.
Publicado: (2022)

Physical activity and sport practice to improve balance control of visually impaired individuals: a narrative review with future perspectives
por: Carretti, Giuditta, et al.
Publicado: (2023)

Myofibroblast transdifferentiation of keratocytes results in slower migration and lower sensitivity to mesoscale curvatures
por: van der Putten, Cas, et al.
Publicado: (2022)

Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
por: Radovits, Tamás, et al.
Publicado: (2009)

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
por: Scheerans, Christian, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease
por: Ghanta, Mohankrishna, et al.
Publicado: (2017)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis
por: Rosa, Irene, et al.
Publicado: (2021)

The crystal structure of the catalytic domain of a eukaryotic guanylate cyclase
por: Winger, Jonathan A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_rpsop8t7ehd0c8ticmrtr9obcf